TLDR:
- Beebe Healthcare’s cardiovascular team was the first in Delaware or Maryland to use the WATCHMAN FLX Pro implant to reduce stroke risk in patients with AFib.
- The device features advanced technology to decrease clot formation and inflammation.
Beebe Healthcare recently became the first healthcare facility in Delaware or Maryland to utilize the WATCHMAN FLX Pro implant in their cardiovascular program. The device is designed to reduce the risk of stroke in patients diagnosed with non-valvular atrial fibrillation, or AFib. This heart rhythm disorder increases the risk for stroke and typically requires long-term anticoagulation medication use.
The WATCHMAN FLX Pro implant offers Hemocoat technology, which helps to decrease clot formation, reduce inflammation, and promote faster healing after the implant procedure. In addition, the device provides enhanced imaging and additional sizing options, making it suitable for a wider range of patients. Beebe Healthcare’s Chief of Cardiology, Dr. Ehtasham Qureshi, emphasized the importance of offering state-of-the-art services and cutting-edge technology to ensure the best possible cardiac care in Sussex County.
Since introducing the WATCHMAN device in 2018, Beebe Healthcare has performed over 200 left atrial appendage closure procedures. The recent milestone of implanting the Amulet device in a patient further demonstrates the cardiovascular team’s commitment to providing innovative and effective treatments for a variety of heart conditions. Beebe Healthcare President and CEO, Dr. David A. Tam, highlighted the impact of these technologies in reducing the risk of stroke and improving patient outcomes.
The successful integration of the WATCHMAN FLX Pro implant in Beebe Healthcare’s cardiovascular program solidifies the organization’s dedication to offering advanced cardiac care options to the community. By staying at the forefront of medical technology and innovation, Beebe Healthcare continues to provide exceptional care for the residents of Sussex County.
